008.2 CAN A RAPID STI SEXUAL HEALTH SERVICE REDUCE GONOCOCCAL CULTURE TESTING WITHOUT REDUCING CULTURE SENSITIVITY? A SERVICE EVALUATION

¹A Tofias*, ²R Gardiner, ³P Muir, ²M Crofts, ²M Clarke, ³P North, ³J Steer, ^{4,5}M Williams, ^{2,6}L Harryman, ^{7,8}J Jackson, ⁹N Childs, ²H Wheeler, ²S Moses, ²P Horner. ¹Bristol Medical School, University of Bristol, Bristol, UK; ²Unity Sexual Health, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; ³PHE South West Regional Laboratory, National Infection Service, Bristol, UK; ⁴Public Health England Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, UK; ⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK; ⁶University of Bristol, Bristol, UK; ⁷The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol, UK; ⁸Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; ⁹Severn Pathology, North Bristol NHS Trust, Bristol, UK

10.1136/sextrans-2021-sti.93

Background The Panther (Hologic Inc) was introduced to our specialist sexual health service at point-of-care, which could provide a rapid gonorrhoea (GC) and chlamydia (CT) nucleic acid amplification test (NAAT) result within 4 hours. GC-culture testing was limited to those testing GC NAAT-positive and/or to those who received treatment before the NAAT result was available. We hypothesised that this would reduce the number of cultures and cost, but not reduce the sensitivity of GC-culture. GC isolates are required for susceptibility testing to optimise antimicrobial therapy and for Anti-microbial Resistance surveillance.

Methods We obtained and compared data on NAATs taken 12 months before and 12 months after the introduction of rapid testing in November 2019. We linked GC-cultures taken within 2 weeks of the NAAT. Chi-square was used to compare proportions.

Results 23,588 CT/GC NAATs were taken before and 21,588 after the introduction of the new rapid STI service of which 684(2.9%) and 766(3.5%) were GC-positive respectively. GC cultures dropped from 10881 to 6022 after November 2019 with the proportion of cultures to NAATs decreasing from 0.46 to 0.28 ($p<0.0001$ Chi-square). This proportion decreased over each 4-month period after November 2019: 0.46(3472/7531), 0.29(1999/6950); and 0.08(551/7107) ($p<0.0001$ Chi-square). There was no significant difference between the proportions of GC NAAT-positive and culture-positive specimens before and after the introduction of the new service: 0.35 (237/684) against 0.35 (265/7660) respectively ($p=1.0$ Chi-square). The proportion of culture-positive specimens was not significantly different in each 4-month period after Nov-2019: 0.36(91/256); 0.38(102/267) and 0.30 (72/243) ($p=0.12$ Chi-square). 86% of NAAT-positive sites had a culture swab taken in the last 4 months compared to >95% in previous 8 months.

Conclusions Implementation of the rapid STI service resulted in fewer GC-culture specimens being taken which reduced the cost of GC-culture but with no loss in GC-culture sensitivity overall.

008.3 DISSEMINATED GONOCOCCAL INFECTION (DGI) IN SEATTLE-KING COUNTY, WASHINGTON (WA), 2006–2020

^{1,2}S McLaughlin*, ^{1,2}L Barbee, ²C Thibault, ^{1,2}M Golden, ^{1,3}O Soge. ¹Department of Medicine, University of Washington, Seattle, USA; ²Public Health – Seattle and King County, HIV/STD Program, Seattle, USA; ³Department of Global Health, University of Washington, Seattle, USA

10.1136/sextrans-2021-sti.94

Background DGI occurs through hematogenous bacterial spread in 0.5–3% of gonorrhea cases. We present a contemporary epidemiologic analysis of DGI in Seattle, King County, WA, USA.

Methods We used STI surveillance data to identify cases of DGI diagnosed 2006–2020 in King County, WA, USA, and abstracted medical records on 27 cases hospitalized in the University of Washington (UW) system.

Results Over 15 years we identified 44 cases. After an outbreak of 19 cases in 2006, Zero-three cases were reported annually except in 2007 and 2020 (5 cases each). Overall, 70% were male ($N=31$). Diagnosis was established by NG culture of synovial fluid (66%, $n=29$), blood (16%, $n=7$), aortic tissue (2%, $n=1$), lymph tissue (2%, $n=1$), and unspecified site (14%, $n=6$). There were no cases of meningitis, infection during pregnancy, or death. Among the 27 cases hospitalized at UW, 78% were male ($n=21$); 59% ($n=16$) presented with polyarthralgia, 85% ($n=23$) with arthritis, 37% ($n=10$) with tenosynovitis; 30% ($n=8$) had fever, 18% ($n=5$) had dermatitis, and 15% ($n=4$) had urogenital symptoms. Most (78%, $n=21$) had NG-positive and purulent (74%) synovial fluid or facial/tendon culture (WBC IQR=54,550–118,000); bacteremia was uncommon (18%, 5/18). Less than half (41%, $n=11$) had urogenital NG testing with few positive (18%, $n=2$). Three of 4 tested had pharyngeal infection and zero of three tested had rectal gonorrhea. Medical management of DGI was highly variable: Although 77% ($n=17$, 5 missing) had at least 3 days of 1–2g IV ceftriaxone initially; the range was wide (0–28 days, IQR 2–6 days). Subsequent IV and/or oral antibiotic class and total antibiotic duration also widely varied (0–60 days, IQR 2–14 days).

Conclusion King County experienced a 2006 DGI outbreak with sporadic cases of uncertain relatedness occurring since. Marked variations in the use of diagnostics and clinical management suggest the need for more consistent management.

008.4 STRENGTHENING THE U.S. RESPONSE TO RESISTANT GONORRHEA (SURRG): A PROGRAM TO ENHANCE LOCAL ANTIBIOTIC RESISTANT GONORRHEA PREPAREDNESS CAPACITY

¹K Schlanger*, ¹K Mauk, ¹E Learner, ¹K Town, ¹C Pham, ²S Bhattacharyya, ³M Sankaran, ⁴J Black, ⁵K Wendel, ⁶C McNeil, ⁷A Fukada, ⁸M Golden, ^{1,9}J Schillinger, ¹R Kirkcaldy. ¹US Centers For Disease Control and Prevention, Atlanta, USA; ²Milwaukee Health Department, Milwaukee, USA; ³San Francisco Department of Public Health, San Francisco, USA; ⁴Indiana State Department of Health, Indianapolis, USA; ⁵Denver Health, Denver, USA; ⁶Wake Forest University, Winston-Salem, USA; ⁷Hawaii Department of Health, Honolulu, USA; ⁸University of Washington, Seattle, USA; ⁹New York City Department of Health and Mental Hygiene, New York City, USA

10.1136/sextrans-2021-sti.95

Background/Purpose In 2016 the U.S. Centers for Disease Control and Prevention (CDC) initiated Strengthening the U.S. Response to Resistant Gonorrhea (SURRG) in local jurisdictions to enhance antibiotic resistant gonorrhea (ARGC) rapid detection and response infrastructure and evaluate the impact of key strategies.

Approach Eight jurisdictions were funded for five years to establish or enhance local specimen collection for gonococcal cultures in STD and community clinics, conduct rapid antibiotic susceptibility testing (AST) using Etest® in local public

health laboratories, modify surveillance systems for enhanced data collection and rapid communication of AST results, and initiate partner services and investigations among patients with GC demonstrating reduced susceptibility (RS) to ceftriaxone, cefixime or azithromycin.

Outcomes/Impact SURRG grantees incorporated robust genital, pharyngeal, and rectal gonococcal culture collection from all genders at participating clinics. During 2018–2019, grantees performed AST on >10,700 isolates with a five-day median turnaround time from specimen collection to reporting AST results to providers. Fifty-nine percent of patients with RS GC returned for a test-of-cure; no resistance-related treatment failures were detected. Among 4,511 isolates, we found $\geq 95\%$ concordance (within one doubling dilution) between AST performed locally using Etest® compared to agar dilution (reference method) for ceftriaxone, cefixime and azithromycin. We conducted investigations among cases and partners, identifying >100 new GC cases. Finally, we merged epidemiologic and partner data with isolate genomic data to further explore sexual networks with GC transmission and identify opportunities for local interventions.

Innovation and Significance SURRG successfully built clinic, laboratory, and epidemiological capacity for local ARGC rapid detection and response. Notable outcomes/innovations include establishing best practices for collecting and transporting gonococcal culture specimens, implementing Etest® in local jurisdictions, and measuring the value of containing ARGC spread through partner services. Lessons learned and project-informed identification of additional ARGC control needs at the local and national level are being used to inform CDC's ongoing ARGC control efforts.

008.5 IMPACT OF INCREASED ASYMPTOMATIC TESTING FOR GONORRHOEA AMONG MSM ON PREP ON THE TRANSMISSION AND DEVELOPMENT OF ANTIMICROBIAL RESISTANCE

¹J Heijne*, ¹M Visser, ²J Riou, ²N Low. ¹National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; ²University of Bern, Bern, Switzerland

10.1136/sextrans-2021-sti.96

Background In many countries, men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP) are routinely three-monthly tested and treated for *Neisseria gonorrhoeae* (gonorrhoea), which might increase antimicrobial resistance (AMR). However, there is uncertainty about how AMR emerges. We investigated the impact of frequent testing and treating on gonorrhoea prevalence and AMR assuming different ways of AMR emergence.

Methods We developed a compartmental model, which included three sexual activity classes that differed in unprotected sex partner numbers and testing uptake. AMR to ceftriaxone was incorporated as stepwise increases in minimum inhibitory concentrations and eventual resistance (MIC drift) in three separate ways: direct selection pressure through ceftriaxone treatment; indirect selection pressure through antimicrobials treatment for other reasons; or imported infection. Each model was calibrated to the ceftriaxone MIC curve from the Dutch Gonococcal Resistance to Antimicrobials Surveillance program (2015–2019). We estimated the impact of three-monthly testing of high-risk MSM on overall and AMR prevalence in 2030.

Results Overall gonorrhoea model prevalence was 3.4% (95% uncertainty interval 3.2%–3.5%), and 14.3% (11.7%–18.0%) in high-risk MSM. Three-monthly testing resulted in 66%–93% reductions in overall prevalence for all three ways in which AMR development was modelled. AMR prevalence was low in 2030 for all three mechanisms, but increased fastest with direct selection compared to indirect or imported. With direct selection, AMR prevalence was 1.7 (1.3–2.0) times higher than with indirect selection and 8.2 (2.7–16.1) times higher than through imported infection. When high-risk MSM increased numbers of unprotected sex partners, three-monthly testing reduced overall prevalence less and AMR prevalence increased, especially with direct selection.

Conclusion With frequent testing of MSM, direct selection pressure through treatment leads to more gonococcal resistance than indirect selection or imported infection. This study highlights the need to increase our understanding of mechanisms of AMR emergence in *N. gonorrhoeae*.

008.6 ASSESSING WITHIN-HOST GENETIC VARIATION IN NEISSERIA GONORRHOEAE AT DIFFERENT ANATOMICAL LOCATIONS AND OVER TIME

^{1,2}J de Korne*, ^{1,3}S Bruisten, ^{4,5}H de Vries, ^{1,2}A van Dam. ¹Department of Infectious Diseases, Public Health Laboratory, Public Health Service of Amsterdam, Amsterdam, The Netherlands; ²Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology, Amsterdam Institute for Infection and Immunity (AII), location Academic Medical Center, Amsterdam, The Netherlands; ³Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity (AII), location Academic Medical Center, Amsterdam, The Netherlands; ⁴Amsterdam UMC, University of Amsterdam, Department of Dermatology, Amsterdam Institute for Infection and Immunity (AII), location Academic Medical Center, Amsterdam, The Netherlands; ⁵STI Outpatient Clinic, Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, The Netherlands

10.1136/sextrans-2021-sti.97

Background Recent trials focus on novel antibiotic treatment options for *Neisseria gonorrhoeae* (Ng), since resistance against currently used cephalosporins is emerging. To assess antibiotic potential, patients with mixed infections or those who are reinfected after treatment should be identified. Comparing levels of within-host genetic variation in Ng isolates at different anatomical locations and over time could identify those patients and could inform thresholds for similarity.

Methods Isolates from the New AntiBiotic treatment Options for uncomplicated GONorrhoea (NABOGO) trial were used in this study. Whole-genome sequences were obtained from paired isolates from 86 patients with multiple isolates from different anatomical locations (n pairs=59) or from different time points (n pairs=48). All isolates were typed according to the typing schemes: NG-Multi-Antigen Sequence Typing (NG-MAST), NG-Sequence Typing for Antimicrobial Resistance (NG-STAR), Multi-Locus Sequence Typing (MLST) and core genome MLST (cgMLST).

Results Identical NG-MAST/NG-STAR/MLST profiles were identified within 93/107 (87%) isolate pairs. Different strains were found in 8/59 (14%) paired isolates from different anatomical locations, according to completely different NG-MAST/NG-STAR/MLST profiles. Five other isolate pairs from multiple anatomical locations differed in NG-MAST but were similar in NG-STAR/MLST. One case of reinfection was identified (1/48, 2%) according to